Viking Therapeutics Begins Exploratory Oral Maintenance Dosing Study Of VK2735, Its Dual Agonist Of Glucagon-Like Peptide 1 And Glucose-Dependent Insulinotropic Polypeptide Receptors

Benzinga

2026.10.06 11:09 (GMT+0)

Abrir en Benzinga